Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, speaks about results from the phase III COMMANDS trial, which he presented during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
The open-label, randomized trial evaluated luspatercept-aamt versus epoetin alfa for the treatment of anemia in adults with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS). All patients in the study required red blood cell transfusions and had not previously received an erythropoietin stimulating agent.
In this video, Dr. Garcia-Manero discusses the study’s primary endpoint, its implications for patients, and the reactions he’s seen to the data he presented during the 2023 ASCO Annual Meeting.
Data from the phase III COMMANDS trial will also be presented during the European Hematology Association Congress on June 10.